MétaCan
Menu
← Back to cohort
Record W4416141275 · doi:10.1093/neuonc/noaf201.0172

BIOM-84. MGMT METHYLATION STATUS REMAINS LARGELY UNCHANGED IN RECURRENT GLIOMA AND INFLUENCES RE-TREATMENT WITH TEMOZOLOMIDE

2025· article· en· W4416141275 on OpenAlexaff
Gabriella Pelofsky, Brianna Suffren, Christine N. Yohn, Aminah Twyman, Christopher A. Febres‐Aldana, Arevik Abramyam, Aparna Sertil, Randy S. D’Amico, Jonathan Sherman, Morana Vojnic

Bibliographic record

VenueNeuro-Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsGovernment of New Brunswick
Fundersnot available
KeywordsTemozolomideMethylationDNA methylationCohortBiomarkerGliomaMethyltransferaseO-6-methylguanine-DNA methyltransferase

Abstract

fetched live from OpenAlex

Abstract BACKGROUND MGMT promoter methylation is a critical biomarker in glioma, predicting response to temozolomide (TMZ) and overall survival. In this study we investigated changes in MGMT methylation status between two sequential glioma samples and explored their clinical implications on clinical decision making. METHODS Data from 533 patients with recurrent glioma in the Caris database were analyzed; 426 had MGMT status available for two sequential tumor samples and were classified as hypermethylated or unmethylated (including equivocal cases). A retrospective chart review was also performed for 28 patients from two institutions, including 10 overlapping with the Caris cohort. RESULTS Among the 426 patients, 84% (358) retained the same MGMT status—52% unmethylated and 32% hypermethylated. Notably, 16% (68) changed status: 11% from hypermethylated to unmethylated and 5% vice versa. Patients who lost hypermethylation had lower initial methylation levels than those who remained hypermethylated (mean difference 13.5 points, p<0.001). Similarly, patients gaining hypermethylation had lower methylation at recurrence compared to consistently hypermethylated cases (mean difference 16.3 points, p<0.001). Time between surgeries was shorter in patients who remained unmethylated (p=0.001) or lost methylation (p=0.006) compared to those consistently hypermethylated. In the clinical cohort (n=28), 86% showed no methylation status change (46% unmethylated, 39% hypermethylated). Four patients (14%) changed status equally in both directions. All but two patients received TMZ after initial resection. At recurrence, 55% of those who remained hypermethylated were re-treated with TMZ, while the rest received investigational therapy or supportive care. CONCLUSION MGMT methylation status remains unchanged in the majority of recurrent gliomas, with change notable in 16% of cases. Clinically, TMZ is frequently used at diagnosis regardless of methylation, but its use appears to be more selective to hypermethylated cases at recurrence. Larger studies are needed to clarify the survival impact of TMZ re-challenge based on methylation changes.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.029
GPT teacher head0.335
Teacher spread0.306 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology→Same topicGlioma Diagnosis and Treatment→French-language works237,207→